Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Children with Moderately to Severely Active Ulcerative Colitis
NCT04624230Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib oral solution in ulcerative colitis (UC), sponsored by Pfizer. Primary endpoint: Remission by central read Mayo score at 44 weeks. Started Aug 2021; status: active, not recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04624230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624230.